To explore therapeutic strategies targeting the E2F1-ASH1L-AS1/APPLE-ERK1/2 axis in HCC, we performed drug sensitivity analysis using the TCGA-LIHC dataset, along with OncoPredict [27] and CTRP2 [28] tools. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.